GroveStreet Managing Director, John Merrill, moderated a panel of GPs exploring sectors of opportunity in venture capital beyond the AI frenzy.  The group explored evolving investment themes in the areas of biotech, healthtech and fintech in North America as well as other innovation centers around the globe. Panelists debated whether or not there is a ‘new dawn’ for biotech or if the current period is just another stage in more of a linear evolution of the space. John wrapped up the discussion by querying the GPs about how they might construct a venture allocation if they were in the seat of a Chief Investment Officer. Not surprisingly, the GPs were bullish on the opportunities in venture.